Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Standard Biotools (LAB) Current Taxes (2022 - 2023)

Standard Biotools (LAB) has disclosed Current Taxes for 2 consecutive years, with $1.2 million as the latest value for Q4 2023.

Quarterly Current Taxes fell 14.76% to $1.2 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2023, down 14.76% year-over-year, with the annual reading at $1.2 million for FY2023, 14.76% down from the prior year.
Current Taxes for Q4 2023 was $1.2 million at Standard Biotools, up from $1.1 million in the prior quarter.
The five-year high for Current Taxes was $1.4 million in Q4 2022, with the low at $1.1 million in Q3 2023.